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Abstract
Background: Japanese encephalitis (JE) is the most important form of viral encephalitis in Asia.
Surveillance for the disease in many countries has been limited. To improve collection of accurate
surveillance data in order to increase understanding of the full impact of JE and monitor control
programs, World Health Organization (WHO) Recommended Standards for JE Surveillance have
been developed. To aid acceptance of the Standards, we describe the process of development,
provide the supporting evidence, and explain the rationale for the recommendations made in the
document.
Methods: A JE Core Working Group was formed in 2002 and worked on development of JE
surveillance standards. A series of questions on specific topics was initially developed. A literature
review was undertaken and the findings were discussed and documented. The group then prepared
a draft document, with emphasis placed on the feasibility of implementation in Asian countries. A
field test version of the Standards was published by WHO in January 2006. Feedback was then
sought from countries that piloted the Standards and from public health professionals in forums
and individual meetings to modify the Standards accordingly.
Results: After revisions, a final version of the JE surveillance standards was published in August
2008. The supporting information is presented here together with explanations of the rationale and
levels of evidence for specific recommendations.
Conclusion: Provision of the supporting evidence and rationale should help to facilitate successful
implementation of the JE surveillance standards in JE-endemic countries which will in turn enable
better understanding of disease burden and the impact of control programs.
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Background
Japanese encephalitis (JE) is a severe disease, with most of
the South-East Asia and Western Pacific WHO-defined
geographical regions at risk. Although JE is acknowledged
as a major public health problem, understanding of the
full impact of the disease is limited by lack of accurate and
comprehensive disease burden data. It has been estimated
that about 175,000 JE cases would occur annually in chil-
dren under 15 years of age in the absence of immuniza-
tion [1]. Reported JE case numbers are much lower, in part
due to JE vaccination programs in several large countries
including China, Japan and Viet Nam. However, with
many JE-endemic countries not conducting surveillance
or not reporting case numbers to the WHO, disease bur-
den in many countries is not well understood and an
accurate estimate of the current global JE case load is not
available. Not only are data lacking, but surveillance data
gathered and reported are not standardized. Reporting
may be based on laboratory-confirmed cases, viral
encephalitis cases, acute encephalitis cases occurring dur-
ing a recognized JE season, or on other mixed criteria. This
lack of consistency can make interpretation of data diffi-
cult.
The WHO publishes standards for surveillance for
selected vaccine-preventable diseases [2]. Surveillance
standards provide guidance for implementation or
strengthening of surveillance systems and encourage con-
sistency in data collection and reporting, thus allowing for
comparability of the information gathered. In 2002 fol-
lowing an international JE meeting held in Thailand, a
group of organizations formed a JE Core Working Group
(CWG) to strengthen and facilitate co-ordination of JE
prevention and control activities. One of the group's ini-
tial activities was drafting JE surveillance standards, and
the final version was ultimately published in August 2008
[2]. The CWG thought it was important to document the
process of developing the standards and the underlying
rationale for the recommendations made. Surveillance
standards developed previously have not always docu-
mented such information, and misunderstandings or con-
troversies have sometimes resulted [3-5]. The objective of
this paper is to provide the rationale for, and describe the
evidence that supports, the recommendations made in the
Standards. Presentation of the rationale will also allow the
future update and interpretation of these standards as
additional data become available.
Methods
Process of development of the Standards
In April 2003, at a meeting of the JE CWG at the WHO
headquarters, discussions began on the JE surveillance
standards. WHO surveillance standards for vaccine-pre-
ventable diseases follow a standard format, including rec-
ommendations on case definition (clinical and laboratory
criteria), types of surveillance, data to be collected and rec-
ommended surveillance performance indicators. The
CWG initially defined a series of important questions to
be addressed within each topic area (Table 1). A system-
atic search was undertaken for literature to address these
questions, which was reviewed at meetings at WHO head-
quarters in July 2004, in Thailand in April 2005, and in
Table 1: Topics and issues considered in development of the Japanese encephalitis (JE) surveillance standards
TOPIC ISSUES CONSIDERED
Clinical case definition Is it possible to clinically differentiate JE from other causes of acute encephalitis?
What symptoms and signs should be included in the case definition for acute encephalitis 
syndrome (AES)?
Should parameters such as age and seasonality be included in the case definition?
Laboratory criteria for confirmation What samples should be used for confirming JE infection, and which are preferred?
What tests are appropriate for confirming JE infection?
What timing should be recommended for collection of samples?
What factors need to be considered in testing for JE virus infection and in interpreting 
test results?
Case classification What case classifications are appropriate based on clinical, epidemiological and laboratory 
findings?
Types of surveillance What is the best model for JE surveillance and are different types of surveillance 
appropriate in different settings?
Minimum data elements, analyses and reporting What data should be collected for analysis and reporting for routine surveillance 
purposes?
What targets should be used to monitor the quality of JE surveillance?
Special aspects What other special aspects of clinical and laboratory surveillance for AES and JE should 
be considered?BMC Infectious Diseases 2009, 9:214 http://www.biomedcentral.com/1471-2334/9/214
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smaller group teleconferences. Emphasis was placed on
the feasibility of implementation of the Standards in
developing country settings, and different surveillance
strategies were included to ensure relevance to countries
based on their local surveillance and laboratory infrastruc-
ture, and JE control status [6].
In January 2006 a field test version of the Standards was
published electronically. During 2006, feedback was
sought from surveillance and disease control managers,
Expanded Program on Immunization (EPI) managers,
and field staff. Several countries including Indonesia, Viet
Nam, and India, piloted the standards, either broadly or
in defined geographical areas. Other forums and meetings
were also used for consultation, including a WHO South-
East Asia regional JE workshop in India in April 2006. All
information gathered was reviewed at a CWG meeting in
Viet Nam in April 2007 and amendments to the Standards
were proposed. A concluding review was undertaken by
the WHO, entailing review by independent external
experts, before final publication in August 2008.
Intended users of the Standards
The Standards are primarily intended for use by staff
responsible for the surveillance of vaccine-preventable or
communicable diseases. However the guidelines also
have implications for clinicians, laboratory managers,
technicians, EPI staff, and other public health profession-
als. They are principally for surveillance purposes; the
CWG recognized that the clinical and diagnostic criteria
for JE for individual patient management may be more
rigorous and vary in different settings.
Type of evidence for the recommendations
A simple, hierarchical grading system has been used in
this paper to categorize the level of evidence supporting
recommendations in the JE surveillance standards (Table
2). It is based on a published system used previously by a
WHO-convened group [7]. Although the recommenda-
tions do not relate to clinical interventions, services or
policies, we felt that providing a simple indicator of evi-
dence would be helpful for users of the Standards.
Results
The evidence gathered to help develop the surveillance
standards, including the findings from the literature
reviews, and rationale for the recommendations, are pre-
sented below. Each component of the standards for which
recommendations were made is discussed, including the
case definition for surveillance, types of surveillance, data
to be collected and surveillance performance indicators.
The level of evidence for each recommendation or topic is
noted.
Clinical case definition
Is it possible to differentiate JE from other causes of acute
encephalitis clinically?
The most commonly recognized presentation of JE virus
(JEV) infection is acute encephalitis [8-11], and it is usu-
ally clinically indistinguishable from other causes of acute
encephalitis syndrome (AES) [12-15]. The Standards
therefore recommend clinical syndromic surveillance to
detect patients with AES, and subsequent laboratory con-
firmation of JEV infection. [Category II]
What symptoms and signs should be included in the case defi-
nition for AES?
The usual clinical presentation of acute encephalitis is
fever, associated with nausea and vomiting, and neuro-
logic symptoms and signs including headache, lowered
level of consciousness, seizures and/or focal neurological
signs [16,17]. Case definitions used for acute encephalitis
in research studies vary, but often focus on the presence of
at least two specific features, including fever (often an
essential component), altered consciousness, headache,
seizures, focal neurological signs, neck stiffness or typical
laboratory parameters [18-20]. Based on this information,
and recognizing the need for a simple case definition to
facilitate surveillance activities, the clinical AES definition
is defined as fever and one or both of a change in mental
status or new onset of seizures. [Category II] Simple febrile
seizures are excluded.
Subsequent evaluation of this definition using a cohort of
63 Vietnamese patients with laboratory-confirmed JE
established its sensitivity and specificity as 65% and 39%,
respectively [15]. Acute flaccid paralysis (AFP) and men-
ingism are also common with JEV infection [10,12,19,21-
23]. Adding either of these criteria improved the sensitiv-
ity to over 85%, but decreased specificity to 26% or 23%
with AFP and meningism, respectively. The CWG did not
consider it justifiable to change the case definition to
include AFP and meningism, as the loss of specificity
would result in substantially greater costs and efforts for
surveillance due to laboratory testing of the additional
cases.
Table 2: Levels of evidence for recommendations in the surveillance standards
Category I Strongly recommended and strongly supported by well-designed experimental or epidemiological studies.
Category II Recommended on the basis of theoretical rationale and suggestive, descriptive evidence.
Category III Recommended on the basis of expert consensus and theoretical rationale.BMC Infectious Diseases 2009, 9:214 http://www.biomedcentral.com/1471-2334/9/214
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Should parameters such as age and seasonality be included in
the case definition?
JE is most commonly seen in Asia in children up to 15
years of age. A high percentage of persons have acquired
immunity by this age due to ongoing environmental JEV
transmission [1,24-27]. However, cases can occur in non-
immune adults and are particularly apparent in this age
group when the virus enters new areas [28-30]. In addi-
tion, age distribution may shift to higher ages when child-
hood JE immunization programs have been implemented
[31-33]. The case definition therefore describes a case as
one occurring in a "person of any age". [Category I] How-
ever in some countries, particularly those at an early stage
of JE control, it may be more feasible and cost-effective to
target surveillance to the under-15 year age group or the
group classified as 'paediatric'.
JEV transmission may be seasonal or year-round
[12,32,34-38]. As AES is caused by multiple different
pathogens, AES cases occur throughout the year. To avoid
lack of reporting of cases at certain times of the year, par-
ticularly during periods considered to be outside the JE
season, the case definition refers to cases occurring "at any
time of the year". [Category I]
Based on the considerations above, a final AES case defi-
nition was derived (Additional file 1).
Laboratory criteria for confirmation
Patients meeting the clinical case definition of AES should
have laboratory testing conducted to determine if the
cause of illness is JEV or another agent. Sample collection
and testing must be as complete as possible.
What samples should be used for confirming JE infection, and
which are preferred?
Detection of immunoglobulin M antibody (IgM) in cere-
brospinal fluid (CSF) is considered the most reliable
method for JE diagnosis [39]. The presence of JEV IgM in
CSF indicates infection of the CNS, proving JEV is the
cause of the patient's encephalitic illness. If CSF is not
available, the diagnosis can be confirmed by presence of
JEV IgM in serum. JEV IgM in serum indicates the patient
is infected with JEV. It does not confirm the patient's
encephalitis is caused by JEV--there is a possibility the
patient could have simultaneous asymptomatic JEV infec-
tion and AES due to another cause. If diagnosis is by
serum alone there is also a greater risk of a falsely positive
test result due to cross-reactivity with co-circulating flavi-
viruses. However, studies have shown most patients who
present with AES during the JE season and have JEV IgM
in serum also have it in CSF and do not have evidence for
a different CNS infection [18,19,40].
The CWG gave careful consideration to whether a positive
CSF result should be the only criteria used to define a "lab-
oratory-confirmed" case in the Standards. However, if
only CSF results were considered, surveillance would lack
sensitivity, with one third of JE cases or more possibly
missed because of both diagnostic testing and sample col-
lection issues as described below.
Firstly, JEV IgM may not be detectable in the CSF of all
patients at presentation to hospital. Studies indicate up to
about 30% of patients may not have detectable JEV IgM
on admission or within a few days of symptom onset [39-
44]. Although JEV IgM continues to increase and is usually
detectable in CSF by day 7 to 8 of illness, a second (con-
valescent) CSF specimen is not, in general, indicated for
clinical management purposes and cannot be recom-
mended for surveillance purposes alone, so many cases
would be missed.
Secondly, lumbar puncture (LP) is not always possible
because of medical contraindications, patient refusal, lack
of appropriate equipment, or if staff have not been trained
or are not comfortable with the procedure. Although CSF
collection is usually the standard procedure in research
studies and good collection rates can be achieved [42],
surveillance programs usually involve large numbers of
health facilities in geographically dispersed areas and
facilities of lower capacity. Although optimal clinical
management of any patient with a suspected CNS infec-
tion includes a LP unless there are contra-indications [45],
especially to exclude treatable conditions like bacterial
meningitis, in some parts of Asia CSF is not always exam-
ined. CSF collection rates of about 30% have been docu-
mented in recent JE surveillance [12,46].
For these reasons, the CWG felt that an AES case with JEV
IgM detected in a single sample of either CSF or serum
should be considered "laboratory-confirmed" to avoid
missing important surveillance information, although
CSF is the preferred specimen. [Category III] Some cases
with JEV IgM in serum and encephalitis due to another
cause may occasionally be incorrectly included as clinical
JE cases, but this is probably a rare event. Studies show
inapparent JEV infection rates in children of about 5%
annually [27,47,48], and it is only if JEV IgM is still
present after inapparent infection that its detection could
result in mistaken attribution of JEV as the cause of the
clinical encephalitis illness. In other words, the positive
predictive value of a JEV IgM positive result in serum in a
patient with encephalitis in a JE-endemic area is likely to
be very high. Furthermore, the presence of JEV IgM in
serum confirms the patient has been infected and there-
fore that JEV is circulating in that area. Inclusion of these
cases is unlikely to result in an overestimate of JE diseaseBMC Infectious Diseases 2009, 9:214 http://www.biomedcentral.com/1471-2334/9/214
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burden if the recognized overall lack of sensitivity of sur-
veillance data is considered [37,49-51].
However, with more widespread introduction of JE vacci-
nation programs, collection of CSF will become increas-
ingly important. After vaccination, JEV IgM may be
detectable in serum but is not present in CSF. If a recently-
vaccinated person develops AES, their illness may errone-
ously be attributed to JE if IgM is detected in serum, even
though there is no IgM in the CSF. This situation has
already been seen in at least one encephalitis outbreak
[52].
What tests are appropriate for confirming JE infection?
For routine surveillance purposes an IgM-capture enzyme-
linked immunosorbent assay (ELISA) specifically for JEV
is considered the standard diagnostic tool [8,26,40].
Other methodologies may be used in reference or research
laboratories, but are not recommended for routine sur-
veillance. Usually, attempts to isolate virus or detect viral
genome with a nucleic acid amplification test in serum or
CSF are unsuccessful, probably because of low viral titres
and the rapid development of neutralizing antibodies
[53-55]. Occasionally JEV has been isolated, or genome
has been detected, in CSF [19,56-60]. Isolates may some-
times be obtained postmortem from brain tissue, and JEV
antigens may be detected by immunohistochemistry or
immunofluorescence assays in brain tissue or CSF
[10,19,29,57,61-63]. Plaque reduction neutralization and
haemagglutination inhibition assays can confirm JEV
infection but are time-consuming and require acute and
convalescent samples to be collected. [Category II](Addi-
tional file 2)
What timing should be recommended for collection of samples?
CSF and serum samples should be routinely collected at
hospital admission for clinical management purposes, as
well as for JE diagnostic testing. However as JEV IgM may
not be detectable during early illness, the Standards rec-
ommend collection of a convalescent serum sample on
the 10th day of illness. In one study involving 60 JE
patients, 100% of patients with serum collected on days 9-
10 of illness had JEV IgM present but only about 80% with
samples collected on days 7-8 had IgM detectable [41].
Another study found 88% (23/26) of patients with sam-
ples collected on days 9-12 of illness had detectable JEV
IgM compared with 70% (31/44) on days 5-8 and 59%
(26/44) on days 1-4 [40]. Patients with JE are typically
admitted to hospital 3 to 4 days after illness onset so the
10th day of illness corresponds to day 7 after hospital
admission [24,43], and another study, measuring from
day of admission, found 100% (19/19) of JE patients had
IgM in serum on day 7 after admission compared with
53% on day 1 [39]. Thus collection of a second serum
sample on day 10 after illness onset (or 7 days after hos-
pital admission) is recommended. [Category I] Although
this time point is preferable, if the patient is due to be dis-
charged earlier, or is very unwell and looks unlikely to sur-
vive to day 10, then an earlier sample should be collected
because any second sample is better than none.
Although collection of CSF and two serum samples is rec-
ommended, the availability and timing of laboratory test-
ing may determine the actual testing conducted. For
example, if the CSF specimen is tested first and is positive,
there is no need to test the sera; if a convalescent serum is
positive, the acute serum need not be tested. However in
some settings it may be most cost-effective and appropri-
ate to test all samples at the same time.
What factors need to be considered in testing for JEV infection
and in interpreting test results?
Antigenic cross-reactivity between flaviviruses is common
and an important issue when conducting serological test-
ing for JEV infection. A patient could have a falsely posi-
tive JEV IgM result if infected with another flavivirus
[41,64-66]. Circulation of dengue virus, a related flavivi-
rus, is common in many JE-endemic areas, and West Nile
or Murray Valley encephalitis viruses also co-exist with
JEV in some areas [12,67]. It is therefore essential that a
representative number of JEV IgM positive samples be
tested for other regionally-relevant flaviviruses and/or
confirmed by the relevant reference laboratory. [Category
I]
Case classification
What case classifications are appropriate based on clinical, epi-
demiological and laboratory findings?
All cases that meet the AES definition (termed "suspected
JE cases") should be included in syndromic AES reporting,
regardless of whether an aetiology other than JE is identi-
fied. Classification of AES cases into one of four sub-
groups--laboratory-confirmed, probable JE, AES-other
agent, or AES-unknown--is based on laboratory testing
and epidemiological findings (Additional file 3). The
rationale for including all cases in AES syndromic report-
ing prior to assigning the specific classification is that the
identification of a particular causal aetiology relies on
access to diagnostic tests, and there is marked variation in
capacity for laboratory testing for encephalitis aetiologies
in individual laboratories and from country to country.
Thus a patient that meets the AES case definition and has
a laboratory-confirmed diagnosis of cerebral malaria, for
example, should be reported as "AES" and classified as
"AES-other agent". If a consistent AES definition is not
applied, regardless of diagnostic capabilities, variations in
reported AES case numbers from site to site could result,
unrelated to actual disease burden. Reporting all AES casesBMC Infectious Diseases 2009, 9:214 http://www.biomedcentral.com/1471-2334/9/214
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also provides evidence that the surveillance is active, even
if no JE cases are occurring.
The classification of "probable JE" enables clear categori-
zation of JE cases during an outbreak. The Standards pro-
pose that after a seasonal outbreak has been laboratory-
confirmed as JE, it may not be necessary to test all remain-
ing outbreak cases (see "Notes", Additional file 2). How-
ever, classifying these cases as "probable JE" (i.e., having a
geographic and temporal link to a laboratory-confirmed
JE case) differentiates them from non-specific "AES-
unknown" cases. This is useful to document the extent of
an outbreak.
Recommended types of surveillance
What is the best model for JE surveillance and are different
types of surveillance appropriate in different settings?
Nationwide syndromic AES surveillance with laboratory
testing of all patients provides the best information on JE
disease burden, epidemiology, and the impact of vaccina-
tion programmes. However, in some countries, this is
logistically complex and would result in a significant
financial burden for the public health system. In such set-
tings, sentinel surveillance may be the appropriate strat-
egy.  [Category III] As most AES cases will present to
hospitals, sentinel surveillance can be hospital-based. In
conjunction with nationwide syndromic AES surveil-
lance--reporting from all health facilities of clinical AES
cases--a selected number of "sentinel" hospitals should
conduct case-based surveillance with laboratory testing of
cases (Additional file 4). This provides information on the
proportion of all AES cases due to JE. If assumptions can
be made that the sentinel site populations are representa-
tive of larger geographical areas and that surveillance is
functioning with reliable completeness and accuracy at
these sites, then information on the proportion of AES
cases confirmed to be JE can be used for broader extrapo-
lations. Using nationwide AES data, for example, national
JE incidence estimates can be approximated. Although
this strategy has limitations, the estimates enable moni-
toring of JE incidence over time. A possible disadvantage
of the sentinel surveillance strategy is that if sentinel hos-
pitals are not located in appropriate geographical loca-
tions or are insufficient in number, JE disease
transmission may be missed. In addition, JE-specific
information to monitor immunization programme per-
formance may not be available to provincial- or district-
level EPI managers.
Minimum data elements, analyses and reporting
What data should be collected for analysis and reporting for
routine surveillance purposes?
Epidemiological and laboratory data elements recom-
mended for collection to enable understanding of disease
burden and monitoring of immunization programs are
provided in the Standards. Variables include age, sex, date
of onset, place of residence, immunization status, travel
history, clinical illness details, laboratory results, and
information on outcome. Suggested analyses are also
defined and can be viewed in full in the Standards. [Cate-
gory III]
What targets should be used to monitor the quality of JE sur-
veillance?
Targets were defined for completeness and timeliness of
reporting (≥ 90% and ≥ 80%, respectively); the percentage
of cases with specimens collected, a serum sample at least
10 days after onset, and samples reaching the laboratory
in adequate condition (≥ 80% for each); and laboratory
results reported in less than one month (≥ 80%). These
performance indicators were considered feasible based on
experience with the use of similar performance indicators
for other vaccine-preventable diseases and on the existing
status of surveillance in JE-endemic countries. They are
only minimum targets and locally-appropriate higher tar-
gets should be defined in countries with strong surveil-
lance systems or as systems improve. [Category III]
The Standards also include a performance indicator for
minimum annual incidence of AES of at least 2 cases per
100,000 population. This is the expected baseline AES
incidence even without JEV transmission (i.e., if at least
two non-JE AES cases per 100,000 population are
reported annually, it suggests the AES surveillance system
is functioning adequately). This figure was derived from a
limited literature review on encephalitis incidence in
industrialized settings where arboviruses are a less promi-
nent cause of encephalitis, thus reflecting encephalitis
rates in the absence of JE. A more extensive literature
review has since been undertaken, reviewing studies from
both industrialized and tropical settings and prioritizing
results from prospective studies as they were stronger
methodologically [68]. It suggested that appropriate min-
imum annual AES incidence targets for children under 15
years of age, adults and all age groups were 10, 2 and 6
cases per 100,000, respectively. Limitations were that a
variety of case definitions and methodologies were used
in the studies; research definitions are likely narrower
than the AES definition used in the Standards; no prospec-
tive childhood study in a tropical area was available; and
epidemiology of acute encephalitis has changed because
of immunization programmes for diseases such as mea-
sles and mumps. In future, the target for minimum AES
incidence may be revised, particularly if additional data
become available. [Category II]
Special aspects
What other special aspects of clinical and laboratory surveil-
lance for AES and JE should be considered?BMC Infectious Diseases 2009, 9:214 http://www.biomedcentral.com/1471-2334/9/214
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The "Special Aspects" section of the Standards discusses
interpretation of laboratory results in a recently-immu-
nized patient, the importance of comprehensive investiga-
tion of AES patients to ensure appropriate clinical
management, and the potential value of integrated
meningoencephalitis surveillance [2].
Testing a single serum sample for JEV IgM within six
months of JE vaccination may not be diagnostic for JE ill-
ness, as JEV IgM may be present in serum after vaccination
[69-72]. The period IgM may remain detectable has not
been accurately determined. Unpublished studies have
shown IgM detectable for at least two months after immu-
nization with inactivated vaccine (J. Cardosa, UNIMAS
Malaysia, personal communication). A study using live,
attenuated SA 14-14-2 vaccine demonstrated IgM in 13%
of children (9/68) one month after vaccination [71]. After
natural JEV infection, IgM persists for 6 months in about
40% of patients, but the IgM response after vaccination is
less vigourous [39,69]. Additional data on IgM persistence
after live JE vaccine are being gathered to help clarify this
issue. [Category II] The Standards list tests that are accept-
able to confirm JE in a recently-vaccinated patient, in par-
ticular testing of CSF. JEV IgM is not present in CSF after
vaccination, so detection of antibody in CSF indicates
wild JEV infection.
Careful investigation of patients is important to ensure
that treatable causes of CNS infection-including malaria,
herpes simplex virus infection and bacterial meningitis-
are not missed. Because several important causes of bacte-
rial meningitis have become vaccine-preventable, and as
there is a clear overlap between patients who meet the
WHO case definitions for "AES" and "bacterial meningi-
tis", the concept of integrated meningoencephalitis sur-
veillance is also discussed in the Standards. This approach
is consistent with clinical management of meningoen-
cephalitis cases, and possible benefits include improved
case detection, reduction in programmatic duplication,
streamlining of logistics, and better use of resources [73].
Discussion
This paper has documented the process undertaken for
developing and refining the WHO JE surveillance stand-
ards, described the rationale for the recommendations
made, and provided the supporting documentation. It
also describes the level of evidence for each topic
addressed. This is expected to support credibility of the
Standards and improve understanding and acceptance of
the recommendations [74].
The CWG focused on developing Standards with feasible
recommendations so implementation is possible in Asian
countries. Strong surveillance is important for document-
ing JE disease burden to assist with decision-making on
vaccine introduction and for monitoring immunization
programmes. It is anticipated this paper will support and
facilitate successful implementation of the WHO JE sur-
veillance standards.
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